[Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice].

Herz
A Osterspey, A Krome

Abstract

The standardized and constant fixed-dose rate, no necessity for a close and regular blood monitoring as well as the small number of interactions with other drugs and daily food make therapy with the new oral anticoagulants dabigatran and rivaroxaban and in future presumably apixaban much easier and more feasible than the standard therapy with vitamin K antagonists (VKA). In summary the trials focusing on patients with non-valvular atrial fibrillation show that the new substances are at least non-inferior or even coequal to the well-known VKAs regarding prevention of thromboembolism. In addition the risk of fatal and especially intracranial hemorrhage can be considered even lower. Furthermore, the trials indicate a trend in reduction of death from any cause in treating these patients with the new drugs. There was no inferiority or even superiority in patient-outcome in extended prevention of venous thrombosis and pulmonary embolism after knee or hip arthroplasty when treating patients with the new substances by oral administration versus subcutaneous administration of low molecular weight heparin. Comparable results were demonstrated in the therapy of patients with acute deep vein thrombosis compared with the standard therapy of...Continue Reading

References

Dec 31, 2005·Stroke; a Journal of Cerebral Circulation·Hiroshi SatoUNKNOWN Japan Atrial Fibrillation Stroke Trial Group
Dec 19, 2007·Circulation·Wayne RosamondUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Apr 2, 2009·The New England Journal of Medicine·Stuart J ConnollySalim Yusuf
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Sep 3, 2010·Der Internist·H VöllerD Westermann
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Dec 24, 2010·The New England Journal of Medicine·Michael Rud LassenUNKNOWN ADVANCE-3 Investigators
Feb 12, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN AVERROES Steering Committee and Investigators
Jul 26, 2011·The New England Journal of Medicine·John H AlexanderUNKNOWN APPRAISE-2 Investigators
Aug 4, 2011·Expert Review of Cardiovascular Therapy·Erica RomualdiWalter Ageno
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Jessica L Mega
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Aug 30, 2011·European Heart Journal·Stefan H Hohnloser, Stuart J Connolly
Nov 15, 2011·The New England Journal of Medicine·Samuel Z GoldhaberUNKNOWN ADOPT Trial Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Nov 25, 2011·The New England Journal of Medicine·Daniel S BudnitzChesley L Richards
Jan 13, 2012·The New England Journal of Medicine·Jeff S HealeyUNKNOWN ASSERT Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.